HIVEC HR: Chemohyperthermia with mitomycin C vs BCG for high-risk non-muscle invasive bladder cancer. Preliminary results from a randomized controlled trial
2019 ◽
Vol 18
(1)
◽
pp. e768-e770
◽
2015 ◽
Vol 14
(2)
◽
pp. e944-e944a
◽
2019 ◽
Vol 37
(3)
◽
pp. 179.e9-179.e18
◽
2012 ◽
Vol 20
(4)
◽
pp. 399-403
◽
2011 ◽
Vol 107
(10)
◽
pp. 1685-1685
◽